The recent developments in migraine represent one of the greatest advances in the field. Novel targeted acute and preventive therapies are prescribed and used in real-world conditions. All of them proved effective and safe in randomized clinical trials (RCTs) but there remain gaps in our understanding. Prospective studies are conducted on a tight schedule and include homogeneous patient populations which represent only a fraction of the patients seen in a headache clinic. Real-world studies can be conducted over longer periods of time with a huge number of cases. In addition, the impact on economic burden and patients' clinical outcomes has received less attention.
The goal of this Research Topic is to bring together a collection of papers that individually and collectively use real-world data to capture the impact of most recent migraine therapies. These data would typically be collected from registries, medical records and patient databases. In so doing, these insights will help to generate new evidence promoting a safe, effective and cost-efficient use
of these medications. The collected real-world evidence (RWE) will support the development of future consensus statements and guidelines to help physicians making decisions about the most appropriate migraine care.
We welcome the submission of manuscripts including, but not limited to, the following topics:
• RWE studies investigating efficacy, safety and treatment patterns in migraine patients and special populations (e.g., highly therapy-refractory patients);
• RWE studies investigating benefits and harms of the concomitant use of anti-CGRP medications, or switching CGRP therapies;
• RWE studies investigating migraine-related healthcare resource utilization and expenditures after the introduction of these innovative therapies.
The articles can be original research, opinion pieces, reviews, systematic reviews, short reports, or case studies.
Dr Pellesi is currently employed at Lundbeck. All other Topic Editors declare no competing interests with regard to the Research Topic subject.
The recent developments in migraine represent one of the greatest advances in the field. Novel targeted acute and preventive therapies are prescribed and used in real-world conditions. All of them proved effective and safe in randomized clinical trials (RCTs) but there remain gaps in our understanding. Prospective studies are conducted on a tight schedule and include homogeneous patient populations which represent only a fraction of the patients seen in a headache clinic. Real-world studies can be conducted over longer periods of time with a huge number of cases. In addition, the impact on economic burden and patients' clinical outcomes has received less attention.
The goal of this Research Topic is to bring together a collection of papers that individually and collectively use real-world data to capture the impact of most recent migraine therapies. These data would typically be collected from registries, medical records and patient databases. In so doing, these insights will help to generate new evidence promoting a safe, effective and cost-efficient use
of these medications. The collected real-world evidence (RWE) will support the development of future consensus statements and guidelines to help physicians making decisions about the most appropriate migraine care.
We welcome the submission of manuscripts including, but not limited to, the following topics:
• RWE studies investigating efficacy, safety and treatment patterns in migraine patients and special populations (e.g., highly therapy-refractory patients);
• RWE studies investigating benefits and harms of the concomitant use of anti-CGRP medications, or switching CGRP therapies;
• RWE studies investigating migraine-related healthcare resource utilization and expenditures after the introduction of these innovative therapies.
The articles can be original research, opinion pieces, reviews, systematic reviews, short reports, or case studies.
Dr Pellesi is currently employed at Lundbeck. All other Topic Editors declare no competing interests with regard to the Research Topic subject.